The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms

The pathogenesis of cancer in human is still poorly understood. With the rapid development of high-throughput sequencing technologies, huge volumes of cancer genomics data have been generated. Deciphering that data poses great opportunities and challenges to computational biologists. One of such key challenges is to distinguish driver mutations, genes as well as pathways from passenger ones. Mutual exclusivity of gene mutations (each patient has no more than one mutation in the gene set) has been observed in various cancer types and thus has been used as an important property of a driver gene set or pathway. In this article, we aim to review the recent development of computational models and algorithms for discovering driver pathways or modules in cancer with the focus on mutual exclusivity-based ones.

[1]  Christopher A. Miller,et al.  Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors , 2011, BMC Medical Genomics.

[2]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[3]  A. Frigessi,et al.  Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.

[4]  Steve Goodison,et al.  Cancer progression modeling using static sample data , 2014, Genome Biology.

[5]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[6]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[7]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[8]  Shihua Zhang,et al.  Toward a systematic understanding of cancers: a survey of the pan-cancer study , 2014, Front. Genet..

[9]  M. Walsh,et al.  The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. , 2014, Cancer cell.

[10]  Shihua Zhang,et al.  Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features , 2015, BMC Genomics.

[11]  Peter J. Campbell,et al.  Evolution of the cancer genome , 2012, Nature Reviews Genetics.

[12]  A. Bashashati,et al.  DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.

[13]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[14]  Shi-Hua Zhang,et al.  Detecting disease associated modules and prioritizing active genes based on high throughput data , 2010, BMC Bioinformatics.

[15]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[16]  Chenguang Wang,et al.  Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma. , 2013, Molecular bioSystems.

[17]  Simo V. Zhang,et al.  A map of human cancer signaling , 2007, Molecular systems biology.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Ling Lin,et al.  PathScan: a tool for discerning mutational significance in groups of putative cancer genes , 2011, Bioinform..

[20]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[21]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[22]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[23]  M. Stratton,et al.  Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.

[24]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[25]  Eytan Ruppin,et al.  Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.

[26]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[27]  G. Parmigiani,et al.  A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.

[28]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[29]  Giovanni Parmigiani,et al.  Patient-oriented gene set analysis for cancer mutation data , 2010, Genome Biology.

[30]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.

[31]  P. Laird,et al.  Discovery of multi-dimensional modules by integrative analysis of cancer genomic data , 2012, Nucleic acids research.

[32]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[33]  Gill Bejerano,et al.  M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity , 2016, Nature Genetics.

[34]  Shi-Hua Zhang,et al.  Efficient methods for identifying mutated driver pathways in cancer , 2012, Bioinform..

[35]  Shi-Hua Zhang,et al.  Identifying multi-layer gene regulatory modules from multi-dimensional genomic data , 2012, Bioinform..

[36]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[37]  Raul Rabadan,et al.  An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. , 2015, Journal of molecular cell biology.

[38]  Shihua Zhang,et al.  Discovery of cancer common and specific driver gene sets , 2016, Nucleic acids research.

[39]  Bo Hu,et al.  Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets , 2015, 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[40]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[41]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[42]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[43]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[44]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[45]  Roded Sharan,et al.  Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..

[46]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[47]  Peter Martin,et al.  Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas , 2014, Genome Biology.

[48]  A. Feinberg,et al.  Increased methylation variation in epigenetic domains across cancer types , 2011, Nature Genetics.

[49]  Luca Laurenti,et al.  Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia , 2014, eLife.

[50]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[51]  David Tamborero,et al.  OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..

[52]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[53]  Laurent Farinelli,et al.  Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. , 2010, Genome research.

[54]  Richard Simon,et al.  Identification of potential synthetic lethal genes to p53 using a computational biology approach , 2013, BMC Medical Genomics.

[55]  C. Yeang,et al.  Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[57]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[58]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[59]  F. Markowetz,et al.  Cancer Evolution: Mathematical Models and Computational Inference , 2014, Systematic biology.

[60]  Shi-Hua Zhang,et al.  Discovery of co-occurring driver pathways in cancer , 2014, BMC Bioinformatics.

[61]  C. Sander,et al.  Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.

[62]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[63]  Martin Vingron,et al.  Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma , 2013, International journal of cancer.

[64]  Shi-Hua Zhang,et al.  Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data , 2013, BMC Systems Biology.

[65]  Richard Simon,et al.  Identifying cancer driver genes in tumor genome sequencing studies , 2011, Bioinform..

[66]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[67]  Niko Beerenwinkel,et al.  Modeling Mutual Exclusivity of Cancer Mutations , 2014, RECOMB.

[68]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[69]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[70]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[71]  É. Remy,et al.  A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. , 2015, Cancer research.

[72]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[73]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[74]  Matthew B. Callaway,et al.  MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.

[75]  Wei-Chung Cheng,et al.  DriverDB: an exome sequencing database for cancer driver gene identification , 2013, Nucleic Acids Res..

[76]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[77]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[78]  Christina Kendziorski,et al.  MADGiC: a model-based approach for identifying driver genes in cancer , 2015, Bioinform..

[79]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[80]  Jun S. Liu,et al.  Inference of transcriptional regulation in cancers , 2015, Proceedings of the National Academy of Sciences.

[81]  Marcel J. T. Reinders,et al.  Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach , 2010, PLoS Comput. Biol..

[82]  C. Sander,et al.  Pattern discovery and cancer gene identification in integrated cancer genomic data , 2013, Proceedings of the National Academy of Sciences.

[83]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[84]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[85]  L. Stein,et al.  A human functional protein interaction network and its application to cancer data analysis , 2010, Genome Biology.

[86]  R. Karchin,et al.  Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. , 2011, Cancer research.

[87]  Teresa M. Przytycka,et al.  MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..

[88]  Eli Upfal,et al.  De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.